Rep. Jehan Gordon-Booth

Filed: 5/6/2024

 

 


 

 


 
10300HB0443ham001LRB103 04013 CES 72218 a

1
AMENDMENT TO HOUSE BILL 443

2    AMENDMENT NO. ______. Amend House Bill 443 by replacing
3everything after the enacting clause with the following:
 
4    "Section 1. Short title. This Act may be cited as the
5Deveraux Hubbard II Blood Clot Prevention and Treatment Act.
 
6    Section 5. Prevention of morbidity and mortality as a
7result of deep venous thromboembolism.
8    (a) The Department of Public Health shall carry out
9projects to increase education, awareness, and diagnosis of
10deep venous thrombosis or pulmonary embolism and to reduce the
11incidence of morbidity and mortality caused by blood clots.
12The projects may be carried out by the Department directly or
13through awards of grants or contracts to public or nonprofit
14private entities. The Department may directly, or through
15awards or grants, provide technical assistance with respect to
16the planning, development, and operation of the projects.

 

 

10300HB0443ham001- 2 -LRB103 04013 CES 72218 a

1    (b) A project under this Section may include:
2        (1) the implementation of public information and
3    education programs for:
4            (A) the prevention of death from deep venous
5        thrombosis or pulmonary embolism;
6            (B) broadening the awards of the public
7        concerning:
8                (i) the risk factors for and the symptoms of
9            deep venous thrombosis or pulmonary embolism;
10                (ii) target populations with greater risk for
11            deep venous thrombosis or pulmonary embolism,
12            including women, seniors, cancer patients,
13            hospitalized patients, pregnant and postpartum
14            women, Black Americans, and those in rural areas;
15            and
16                (iv) the public health consequences of deep
17            venous thrombosis or pulmonary embolism; and
18            (C) increasing screening, detection, and diagnosis
19        of deep venous thrombosis or pulmonary embolism; and
20        (2) surveillance of the prevalence and incidence of
21    deep venous thrombosis or pulmonary embolism to improve
22    patient outcomes.
23    (c) The Department may, in awarding grants or entering
24into contracts under this Section, give priority to entities
25seeking to carry out projects that target the populations
26referred to in item (ii) of subparagraph (B) of paragraph (1)

 

 

10300HB0443ham001- 3 -LRB103 04013 CES 72218 a

1of subsection (b).
2    (d) The Department shall ensure that projects carried out
3under this Section are coordinated, as appropriate, with other
4agencies that carry out activities regarding deep venous
5thrombosis or pulmonary embolism.
6    (e) The Department shall:
7        (1) collect and analyze the findings of research
8    conducted with respect to deep venous thrombosis or
9    pulmonary embolism; and
10        (2) taking into account such findings, publish on the
11    Department's website the best practices for physicians and
12    other health care providers who provide care to
13    individuals with deep venous thrombosis or pulmonary
14    embolism.
 
15    Section 10. Advisory Committee for Deep Venous Thrombosis
16or Pulmonary Embolism Prevention.
17    (a) Not later than 180 days after the effective date of
18this Act, the Director of Public Health shall establish an
19advisory committee to be known as the Advisory Committee for
20Deep Venous Thrombosis or Pulmonary Embolism Prevention.
21    (b) The Advisory Committee shall:
22        (1) identify the aggregate number of individuals in
23    the State who experience deep venous thrombosis or
24    pulmonary embolism annually;
25        (2) identify how data are collected regarding deep

 

 

10300HB0443ham001- 4 -LRB103 04013 CES 72218 a

1    venous thrombosis or pulmonary embolism and the adverse
2    outcomes associated with such conditions;
3        (3) identify how deep venous thrombosis or pulmonary
4    embolism impacts the lives of individuals in the State;
5        (4) identify the standard of care for deep venous
6    thrombosis or pulmonary embolism surveillance, detection,
7    and treatment;
8        (5) identify emerging treatments, therapies, and
9    research relating to deep venous thrombosis or pulmonary
10    embolism;
11        (6) develop recommendations to help health care
12    providers identify patients who may be at a higher risk of
13    forming deep venous thrombosis or pulmonary embolism in
14    health care facilities;
15        (7) develop recommendations to help improve patient
16    awareness of deep venous thrombosis or pulmonary embolism;
17        (8) develop recommendations with respect to the
18    standard of care for patients at risk of forming deep
19    venous thrombosis or pulmonary embolism;
20        (9) develop recommendations relating to providing
21    patients and their families with written notice of
22    increased risks of forming deep venous thrombosis or
23    pulmonary embolism; and
24        (10) identify the estimated level of State funding
25    needed for deep venous thrombosis or pulmonary embolism
26    services to meet the needs of high-risk populations.

 

 

10300HB0443ham001- 5 -LRB103 04013 CES 72218 a

1    (c) The Advisory Committee shall be composed of members
2appointed by the Director as follows:
3        (1) at least one individual who has experienced blood
4    clots;
5        (2) at least one family member of an individual who
6    died from deep venous thrombosis or pulmonary embolism;
7        (3) at least one health services researcher;
8        (4) at least one health care provider;
9        (5) at least one representative of a health plan;
10        (6) at least one representative of a hospital or
11    health system;
12        (7) at least one epidemiologist;
13        (8) at least one public health expert;
14        (9) at least one patient representative or
15    representative of a patient group;
16        (10) at least one physician licensed to practice
17    medicine in all its branches and who represents a
18    statewide organization of physicians; and
19        (11) such individuals representing other interested
20    parties or associations, as the Director determines
21    appropriate.
22    (d) Not later than 18 months after the first meeting of the
23Advisory Committee, the Director shall submit to the General
24Assembly, and make publicly available, a report:
25        (1) summarizing the meetings and findings of the
26    Advisory Committee; and

 

 

10300HB0443ham001- 6 -LRB103 04013 CES 72218 a

1        (2) describing the recommendations of the Advisory
2    Committee for legislative and administrative action to
3    improve deep venous thrombosis or pulmonary embolism
4    prevention, treatment, and diagnosis, including the
5    recommendations described in paragraphs (6) through (9) of
6    subsection (b).
7    (e) The Advisory Committee shall terminate on the earlier
8of:
9        (1) the date on which the Director submits the report
10    under subsection (d); or
11        (2) the date that is 18 months after the first meeting
12    of the Advisory Committee.
 
13    Section 15. Deep venous thrombosis or pulmonary embolism
14surveillance study and report.
15    (a) The Department of Public Health shall conduct or
16support a study on model systems of deep venous thrombosis or
17pulmonary embolism surveillance, including the use of
18electronic medical record-based methods of detecting deep
19venous thrombosis and pulmonary embolism, International
20Classification of Diseases codes, or other population-based
21surveillance.
22    (b) Not later than one year after the effective date of
23this Act, the Department shall submit to the General Assembly
24and the Advisory Committee for Deep Venous Thrombosis or
25Pulmonary Embolism a report detailing the results of the study

 

 

10300HB0443ham001- 7 -LRB103 04013 CES 72218 a

1under subsection (a).".